Bio-Rad Laboratories Inc. logo

Bio-Rad Laboratories Inc. (BIO)

Market Open
14 Jul, 16:49
NYSE NYSE
$
252. 07
-4.9
-1.91%
$
7B Market Cap
- P/E Ratio
0% Div Yield
22,824 Volume
11.51 Eps
$ 256.97
Previous Close
Day Range
249.02 254.01
Year Range
211.43 387.99
Want to track BIO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 16 days
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms

Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms

BIO surges 4% as the Stilla acquisition fuels the launch of four ddPCR systems, expanding to 400K+ assay offerings.

Zacks | 3 hours ago
New Strong Sell Stocks for July 10th

New Strong Sell Stocks for July 10th

BIO, DECK and ELUXY have been added to the Zacks Rank #5 (Strong Sell) List on July 10, 2025.

Zacks | 4 days ago
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends

Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends

Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Zacks | 2 months ago
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket

BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket

Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.

Zacks | 2 months ago
Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2025 Earnings Conference Call May 1, 2025 5:30 PM ET Company Participants Edward Chung - Head of Investor Relations Jon DiVincenzo - President and Chief Operating Officer Roop Lakkaraju - Executive Vice President and Chief Financial Officer Norman Schwartz - Chief Executive Officer Conference Call Participants Patrick Donnelly - Citigroup Dan Leonard - UBS Brandon Couillard - Wells Fargo Conor McNamara - RBC Capital Markets Jack Meehan - Nephron Research Operator Ladies and gentlemen, thank you for standing by. My name is Desyree, and I will be your conference operator today.

Seekingalpha | 2 months ago
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates

Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $2.29 per share a year ago.

Zacks | 2 months ago
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 2 months ago
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.

Zacks | 3 months ago
Bio-Rad (BIO) International Revenue Performance Explored

Bio-Rad (BIO) International Revenue Performance Explored

Review Bio-Rad's (BIO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks | 4 months ago
BIO Stock Might Rise Following the Offer to Acquire Stilla

BIO Stock Might Rise Following the Offer to Acquire Stilla

Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.

Zacks | 4 months ago
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.

Zacks | 4 months ago
Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Conference Call Participants Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Conor McNamara - RBC Capital Markets Tycho Peterson - Jefferies Operator Thank you for standing by. My name is Prila [ph] and I will be your conference operator today.

Seekingalpha | 5 months ago
Loading...
Load More